Study Published in Nature Digital Medicine Shows Potential of Machine Learning and Augmented Reality-based Digital Biomarkers in Alzheimer’s Detection

Meet Our Leadership Team

Our multi-disciplinary team of scientists, entrepreneurs, and technologists have united to create the future of precision neurology diagnostics. We are dedicated to building a next-generation digital biomarkers platform that could revolutionize the field.
Through the power of our proprietary machine-learning and augmented-reality technology, we are developing a precision neurology platform intended to redefine the industry standard. With our exceptional partner operations and platform delivery functions, we are continuously striving to redefine what it means to deliver a best-in-class service.
Our mission extends beyond simply offering solutions - we strive to make a transformative impact on healthcare within the field of neurological disease. By pushing the boundaries of what is possible, we hope to pave the way for a new era in healthcare and scale our industry-defining solutions to improve the lives of countless individuals, their families and healthcare providers.

Executive Leadership


Board of Directors

Shayn is a Partner at Whitecap and joined the firm in 2015. Prior to joining Whitecap, Shayn was a lawyer at the corporate law firm Wildeboer Dellelce LLP. Shayn is active in the community, including involvement with Sunnybrook Health Sciences Centre and Sick Kids Hospital. Shayn holds a JD and an MBA from Queens University and a BA (Philosophy) from Western University.
Arnd has collected a broad and long-standing experience in building and exiting ventures in the healthcare sector. He served as chairman and board director of companies such as Esbatech (acquired by Alcon), Kuros Biosurgery (reverse-IPO at SWX), Activaero (acquired by Vectura), or Ganymed Pharmaceuticals. In his previous career, he built a team dedicated to venture capital transactions in the healthcare industry for KPMG Corporate Finance. He gained his entrepreneurial experience in several Medical Device and Digital Health startups where he held various senior management positions in marketing, commercialization, and product development. As an MD he started his professional career in two university hospitals as an anaesthesiologist and in medical research. In addition to being an MD, Arnd also holds an MBA from the Kellogg Graduate Business School, USA, and WHU Koblenz, Germany, as well as a Postgraduate Degree in Computer Sciences from TU Munich, Germany.
Therese Maria (Thera) is an Investment Director in the Biotechnology team of M Ventures. Thera actively leads investments and represents M Ventures on the board of multiple portfolio companies. Previously Thera managed strategic projects for the Healthcare business of Merck and prior to this was a client relationship manager in the field of wealth preservation, at Industrie- & Finanzkontor Ets. She received her PhD in Immuno-Oncology from University College London, an MSc in Biomedical Sciences from the University of Amsterdam, and a BA in Biology and Business studies from New York University.
William Moffitt is an accomplished chief executive and board chairman with a proven track record of leading corporations --- of all market capitalizations, public and private --- in the rapid development of cutting-edge technologies and the commercialization of products and solutions that have helped shape the healthcare industry. From innovative, high-tech start-ups to larger more mature companies, Mr. Moffitt possesses demonstrated ability to attract and maintain Wall Street support at all stages of a company’s development. Until his retirement in early 2013, Mr. Moffitt was President, Chief Executive Officer and a director of Nanosphere, a developer, manufacturer and marketer of an advanced molecular diagnostic platform for the early detection of disease. Under his leadership Nanosphere transformed itself from a development stage company to a publicly listed commercialization company with a pipeline of products to drive continued growth and profitability. Prior to his tenure at Nanosphere, he was President, Chief Executive Officer and a director of i- STAT Corporation, a developer, manufacturer and marketer of diagnostic products that pioneered the point-of-care blood analysis market. Moffitt led i-STAT from its early research stage to commercialization and through its initial public offering to its premium acquisition by Abbott Laboratories in 2003. Prior to i-STAT Moffitt held executive positions at Baxter Healthcare Corporation, a manufacturer and distributor of health care products, and American Hospital Supply Corporation, a diversified manufacturer and distributor of health care products, which Baxter acquired in 1985. Moffitt has been a director and chairman of numerous private and public medical technology companies, commencing in the development stage progressing through to successful exits for many. Currently, Moffitt serves as chairman of Altoida, chairman of First Light Bioscience and chairman of Momentum BioScience, Ltd. Moffitt earned a B.S. from Duke University.